Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 1A-B (Cert # L239181)
ACPE Numbers: Various – see listing below
Pre-Sale Date: 02/22/2023
Content Release Date: 03/22/2023
Expiration Dates: 09/26/2023
Activity Type: Application-based
CE Credits: 8 contact hours
Activity Fee: $160 (ASHP member); $215 (non-member)
The Home Study Syllabus is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.
Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
These recertification activities are intended for board-certified pharmacists seeking to update their knowledge and skills in:
- Pediatric Malignancy
- Hepatocellular Carcinoma
- Urothelial Carcinoma
- Pharmacy Practice Management
Board certified pharmacists are eligible to receive up to 8 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.
Contact Hours (ACPE & BPS)
Assessment Pass Point
Home Study Syllabus Module 1A: Pharmacogenomics, Statistics, Pediatric Malignancy
|Home Study Syllabus Module 1B: Hepatocellular Carcinoma, Urothelial Carcinoma, Pharmacy Practice Management, Lymphoma||
Articles and Learning Objectives
Module 1A: Pharmacogenomics, Statistics, Pediatric Malignancy
ACPE #: 0204-9999-23-952-H01-P
Chekravarty D et al. Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2020; 40(11):1231-58.
- Describe the provisional clinical opinion from the American Society of Clinical Oncology (ASCO) for the use of somatic genomic testing and biomarker-guided therapies in patients with metastatic or advanced cancer.
- Develop recommendations for the use of somatic genomic testing and biomarker-guided therapies in patients with metastatic or advanced cancer.
- Select appropriate patients to receive biomarker-guided therapies based on the ASCO provisional clinical opinion for somatic genomic testing.
Anagnostou V et al. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. Clin Cancer Res. 2017; 23:4959-69.
Doki Y et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022; 386:449-62.
- Describe various endpoints used in an immuno-oncology trial.
- Select appropriate patients to receive nivolumab in combination for a patient with advanced esophageal squamous-cell carcinoma based on the results of an immuno-oncology trial.
- Interpret an immuno-oncology trial using nivolumab in combination for a patient with advanced esophageal squamous-cell carcinoma.
Brown PA, Ji L, Xu X et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021; 325(9):833–842.
- Describe the study of blinatumomab for relapsed B-cell acute lymphoblastic leukemia in children, adolescents and young adults with first relapse.
- Select appropriate patients to receive blinatumomab based on the results of the study by Brown, et al.
- Develop recommendations for the management of first relapse of B-cell acute lymphoblastic leukemia in children, adolescents and young adults.
Module 1B: Hepatocellular Carcinoma, Urothelial Carcinoma, Pharmacy Practice Management, Lymphoma
ACPE #: 0204-9999-23-953-H01-P
Kelley et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23: 995–1008.
- Describe the COSMIC-312 study of cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma.
- Develop recommendations for the use of cabozantinib plus atezolizumab in patients with advanced hepatocellular carcinoma.
- Select appropriate patients to receive cabozantinib plus atezolizumab based on the results of the COSMIC-312 study.
Barjorin DF et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021; 384:2102-14.
- Describe the study of adjuvant nivolumab for muscle-invasive bladder cancer in newly diagnosed patients following surgical resection.
- Develop recommendations for the use of adjuvant nivolumab in patients with muscle-invasive bladder cancer.
- Select appropriate patients to receive adjuvant nivolumab based on the results of CheckMate 274 by Bajorin et al.
Nahleh Z, Lyman GH, Schilsky RL et al. Use of biosimilar medications in oncology. J Oncol Pract. 2022; 18:177-86.
- Describe the overview of biosimilar agents for the therapeutic use in cancer from the American Society of Clinical Oncology (ASCO).
- Develop recommendations for the use of biosimilars for therapeutic use in oncology patients and inclusion in future ASCO clinical guidelines.
- Select appropriate patients to receive biosimilar medications based on the ASCO summary of the current agents available for the therapeutic treatment of cancer.
Kamdar M, Solomon S, Arnason J et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022; 399(10343):2294-2308.
- Describe the TRANSFORM study of lisocabtagene maraleucel versus the standard of care for the second-line treatment of relapsed or refractory large B-cell lymphoma.
- Develop recommendations for the use of lisocabtagene maraleucel for the second-line treatment of diffuse large B-cell lymphoma.
John Bossaer, PharmD, BCPS, BCOP
Bill Gatton College of Pharmacy at ETSU
Johnson City, Tennessee
Courtney C. Cavalieri, PharmD, BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
Karen M. Fancher, PharmD, BCOP*
Associate Professor of Pharmacy Practice/ Clinical Pharmacy Specialist - Oncology
Duquesne University School of Pharmacy/UPMC Passavant Hospital
Christopher Fausel, PharmD, MHA, BCOP
Clinical Specialist – Precision Medicine
Indiana University Simon Comprehensive Cancer Center
Elyse MacDonald, PharmD, MS, BCPS
Director, Pharmacy Services, Investigational Drug Service
Stanford Health Care
Palo Alto, California
Janelle Mann, PharmD, BCOP
Clinical Oncology Pharmacist/Manger, Clinical Pharmacy Services
Alvin J. Siteman Cancer Center/Washington University School of Medicine in St. Louis
St. Louis, Missouri
Danielle Roman, PharmD, BCOP*
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Christine M. Walko, PharmD, BCOP, FCCP*
Associate Member, Individualized Cancer Management
H. Lee Moffitt Cancer Center
Jennifer Young, PharmD, BCOP
Clinical Pharmacy Specialist – Pediatric Oncology
Cincinnati Children’s Hospital Medical Center
*Content Matter Experts
Angela T. Cassano, PharmD, BCPS, FASHP
John Adamchick, PharmD, BCOP
Briana Amundson, PharmD, BCOP
Jonathan Angus, PharmD, BCOP
Linda Arrabi, PharmD, BCOP
Laura Atack, PharmD, BCPS, BCOP
Chase Ayres, PharmD, BCOP
Allison Bass, PharmD, BCOP
Christopher Bell, PharmD, BCOP
Bailee Binks, PharmD, BCOP
Eric Boateng, PharmD, BCOP
Debra Chibroski, RPh, PharmD, BCOP
Gregory Clark, PharmD, BCOPP
Bryant Clemons, PharmD, BCOP
Jill Comeau, PharmD, BCOP
Brian Crandell, PharmD, BCOP
Bryna Delman Ewachiw, PharmD, BCOP
Gloria Espinosa, PharmD, MAT, BCOP
Atefeh Fahimi, PharmD, APh, BCOP
Ansley Fancher, PharmD, BCOP
Lora Ferguson, PharmD, BCOP, CSP
Christina Fullerton, PharmD, BCOP
Jonathan Gerber, PharmD, BCPS, BCOP
David W Harris, PharmD, BCOP
Hailey Hill, PharmD, BCOP
Jerline Hsin, PharmD, BCPS, BCOP
Christine Hughes, PharmD, BCOP
Anna Jan, PharmD, BCOP
Lukose Joseph, PharmD
Chris Kapolas, PharmD, BCOP
Dasse Kathy, PharmD, BCOP
Donna Kido, PharmD, BCOP
Elizabeth Koselke, BCOP
Ashton Koskosky, PharmD, BCOP
Beatrix Lam, PharmD, BCPS, BCOP
Lesli Lavery, PharmD, BCOP, CPP
Christopher Lee, PharmD, BCOP
Michael Leung, PharmD, BCOP
Katherine Lin, PharmD, BCOP
Linda Linderbeck, PharmD, BCOP
Jonathan Malara, PharmD, BCOP
Margaret McCallen, PharmD, BCOP
Jeanne McCarthy-Kaiser, PharmD, BCOP
Deborah McCue, PharmD, BCOP
Jessica McElwee, PharmD, BCPS
Ashley McGee, PharmD, BCOP
Frank Mistretta, PharmD, BCOP
Katlyn Mulhall, PharmD, BCOP
Danielle Murphy, PharmD, BCOP, BCPS
Heather Nelkin, PharmD, MBA, BCOP, DPLA
Van Nguyen, PharmD, BCOP
Jeanne Noe, PharmD, BCOP
Kelly K. Nystrom, PharmD, BCOP
Chukwuemeka Nzelibe, PharmD, BCOP
Laura Olson, RPh, BCOP, BCPS
Megan Ouldhouse, RPh, BCOP
Marie Parish, PharmD, BCOP, BCPS
Jooyoung Park, PharmD, BCOP
Mike Reed, BCOP, BCCCP
Kelly Richard, PharmD, BCOP
Forrest Ridgway, PharmD, BCPS, BCOP
Hope Schenk, PharmD, BCOP
Jon Shaffer, PharmD, BCOP
Amanda Sirisaengtaksin, PharmD, BCOP
Janine Smith, PharmD, BCPS, BCOP
Anne Spengler, PharmD, BCOP
James Sturgeon, PharmD, BCPS, BCOP
Anna Sweet, PharmD, BCOP
Marc Takemoto, PharmD, BCOP
Eryn Whitaker, PharmD, BCOP
Christine Williams, PharmD, BCPS, BCOP
Justin Woods, PharmD, BCPS, BCOP
Chen Xu, PhD, BCOP
Lily Yan, PharmD, BCOP
Barbara Yim, PharmD, BCOP
Carolnn Yong, PharmD, BCPS, BCOP
Mark Zangardi, PharmD, MS, BCOP
Relevant Financial Relationship Disclosure
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
- Karen Fancher: Consultant, AstraZeneca, Merck
- Courtney Cavilieri: Consultant, Pfizer
- All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.
Methods and CE Requirements
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
ASHP collaborates with ACCP on oncology pharmacy activities.